Clinical Trials
-
Principal Investigator:
Thomas H. Brannagan III, MDThis is a Phase 3, randomized, double blind, study evaluating efficacy and safety of riliprubart versus intravenous immunoglobulin (IVIg) in participants with chronic inflammatory demyelinating polyneuropathy. Overall the study will last about 109 weeks (2 years) . Participants must be 18 years old at the time of signing the informed consent form. -
Principal Investigator:
Thomas H. Brannagan III, MDThe purpose of this study is to evaluate the safety, tolerability and effectiveness of VX-548 in participants with pain due to Diabetic Peripheral Neuropathy (DPN). To be in this study you must have DPN and be 18 through 80 years of age, inclusive, with presence of bilateral pain in lower extremities due to DPN for at least 1 year. -
Principal Investigator:
Christiane Reitz, MD, PhDWe are recruiting individuals and/or families with members under the age of 65 who have dementia or are experiencing memory problems. Our initial screening can be completed in person or over the phone. The evaluation will take about 1 to 1.5 hours per person and includes a: 1. Blood sample (5 tablespoons) or saliva (1 teaspoon) collection: These blood samples will allow us to examine genes to identify causative mutations. 2. Brief Neuropsychological Assessment. 3. Medical History: A research physician will collect basic medical information on you and your family. This assessment will provide... -
Principal Investigator:
Thomas H. Brannagan III, MDWhy is this study being done? This research is looking at a possible new treatment for people who have ongoing pain from a condition called small fiber neuropathy and haven't found relief from other treatments. How does the study work? This is a double-blind study. That means you won't know whether you are getting the real treatment (ST-503) or a sham (a fake treatment with no effect), and most of the study team won't know either. This helps make the results fair and reliable. What is the study treatment? The study is testing a new kind of treatment called gene therapy. The drug being studied... -
Principal Investigator:
Philip L. De Jager, MD, PHDGenes and Environment in MS (GEMS) is a longitudinal cohort study investigating how genetics and environment can lead to the onset of Multiple Sclerosis. We are recruiting first-degree relatives (siblings, parents, and children) of people who have been diagnosed with MS. This study involves the collection of magnetic resonance imaging (MRI) of the brain, biological specimen, including saliva and blood, as well as the completion of questionnaires regarding personal and family health history, diet, and other environmental exposures. The goal of this study is to use these data to develop and... -
Principal Investigator:
Philip L. De Jager, MD, PHDGenes and Environment in MS (GEMS) is a longitudinal cohort study investigating how genetics and environment can lead to the onset of Multiple Sclerosis. We are recruiting first-degree relatives (siblings, parents, and children) of people who have been diagnosed with MS. This study involves the collection of magnetic resonance imaging (MRI) of the brain, biological specimen, including saliva and blood, as well as the completion of questionnaires regarding personal and family health history, diet, and other environmental exposures. The goal of this study is to use these data to develop and... -
Principal Investigator:
Giuseppe Tosto, MD, PhDThis study aims to find genes that cause Alzheimer's Disease in African Americans and Hispanics/Latinos. Participants are eligible if African American or Hispanic/Latino and 60 years of age or older. Study participation would entail completing a memory assessment, having their blood drawn, and a brief physical exam with a questionnaire. Compensation of $50 will be provided, if unable to come to Columbia University Irving Medical Center, home visits are available. Participants can live anywhere in the US. -
Principal Investigator:
Philip L. De Jager, MD, PHDThe purpose of this study is to establish a collection of biological fluids and associated data from healthy individuals to determine how genetic and environmental variation affects the immune system. Study visits consist of taking vitals and collecting biological fluids, such as blood. You will be compensated for participating in this study. -
Principal Investigator:
Dritan Agalliu, PhDThe aim of this study is to understand the mechanisms of secondary effects of traumatic brain injury on the blood-brain barrier and to understand the biochemical differences in the blood of people with Alzheimer's disease and the volunteer group. We will compare biochemical blood differences between a healthy group and traumatic brain injury patients and Alzheimer's disease. Our aim is to identify biochemical changes in the blood that may worsen the prognosis in traumatic brain injury and Alzheimer's disease. We are looking for healthy volunteers in certain age groups (18-30, 35-55, 60-80)...